GleamWall
中文EN

LAB STANDARD BIOTOOLS INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1162194 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-2.2%
TTM net income YoY203.8%
TTM EPS YoY203.0%
Revenue 3-yr CAGR-7.1%
Net income 3-yr CAGR—

Margins

Gross margin52.2%
Operating margin-97.5%
Net margin157.6%
FCF margin-77.8%
EBITDA margin-91.3%

Returns

ROE27.9%
ROA22.7%
ROIC (approx.)-23.4%
Asset turnover0.14x

Leverage & solvency

Liabilities / assets12.5%
Debt / equity0.00x
Current ratio9.75x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.48x
Accruals ratio33.6%
Payout ratio—
Capex / revenue1.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$85.33M$91.01M$106.34M$97.95M$130.58M
Cost of revenue$42.79M$46.12M$55.89M$60.90M—
Gross profit$42.54M$44.88M$50.45M$37.05M—
R&D expense$25.99M$28.83M$25.95M$37.38M$37.94M
SG&A expense$109.86M$103.06M$87.54M$102.28M$98.89M
Operating income-$110.25M-$127.48M-$76.60M-$116.20M-$67.46M
Interest expense——$4.57M$4.33M$3.82M
Pretax income-$96.70M-$90.40M-$74.20M-$192.93M-$63.66M
Income tax-$37.88M$542,000$452,000-$2.83M-$4.42M
Net income-$74.90M-$138.88M-$74.66M-$190.10M-$59.24M
EBITDA-$100.99M-$114.97M-$72.62M-$113.41M-$64.24M
EPS (basic)-0.20-0.52-0.94-2.43-0.78
EPS (diluted)-0.20-0.52-0.94-2.43-0.78
Weighted avg. shares (diluted)381.62M353.25M79.16M78.31M75.79M
Balance sheet
Cash & equivalents$120.86M$168.82M$52.50M$82.32M$29.47M
Short-term investments$66.71M$126.15M$63.19M$84.47M$0
Receivables$13.43M$14.74M$19.66M$17.28M$18.32M
Inventory$19.98M$20.74M$20.74M$21.47M$20.82M
Current assets$454.26M$375.88M$158.22M$208.81M$72.07M
PP&E, net$19.27M$22.77M$24.19M$25.65M$28.03M
Goodwill—$111.30M$106.32M$106.25M$106.38M
Intangibles—$28.95M$1.40M$12.60M$27.93M
Total assets$567.75M$612.35M$323.07M$390.31M$275.21M
Current liabilities$108.31M$65.89M$109.33M$43.44M$49.57M
Long-term debt—$299,000$63.51M$64.89M—
Total debt—$299,000$63.51M$64.89M—
Total liabilities$143.46M$140.62M$159.87M$160.52M$180.62M
Shareholders' equity$424.29M$471.72M-$148.05M-$81.47M$94.60M
Net debt—-$168.52M$11.01M-$17.43M—
Shares outstanding386.38M377.53M80.23M79.48M76.92M
Cash flow statement
Operating cash flow-$74.34M-$143.45M-$43.29M-$89.37M-$44.06M
Capital expenditure$8.30M$8.36M$2.83M$3.83M$13.26M
Free cash flow-$82.65M-$151.81M-$46.12M-$93.19M-$57.33M
Investing cash flow$27.41M$363.17M$20.24M-$88.13M-$11.95M
Financing cash flow$570,000-$102.62M-$6.81M$230.76M$15.96M
Depreciation & amortization$9.26M$12.52M$3.98M$2.80M$3.22M
Stock-based compensation$29.61M$31.73M$13.12M$14.88M$16.10M
Share buybacks$0$40.49M$5.41M$563,000$0

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.